Organogenesis Holdings Inc.(ORGO)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Organogenesis faces a binary risk profile driven by its heavy reliance on Medicare reimbursement codes, which creates extreme quarterly revenue fluctuations such as the 57.1% contraction seen in 2026Q1.
• While the company maintains a conservative capital structure with a 0.19 debt-to-equity ratio, the inability to achieve consistent operating leverage—evidenced by SG&A expenses remaining between $65 million and $100 million—suggests that long-term profitability remains precarious.
• Investors should monitor the sustainability of the company's high-cost, cold-chain distribution model, as any adverse regulatory shift could impair the $157.8 million in net PPE assets.